It is postulated that the volume reduction of duct blood units in albumin or dextran before infusion into patients leads to improved cell viability. to urge the simplest stem cells possible, it's best to require them within the duct blood. they will then be stored during a cord bank or somatic cell bank for the simplest cord blood collection.
This is supported an in vitro study, which showed that the somatic cell viability could actually be improved by volume reducing the duct blood units before the infusion to revive the osmolarity of the suspension.
It was suggested that this process could protect the stem cells from the severe osmotic stress related to the infusion of cells suspended in a medium with high concentrations of dimethyl-sulfoxide.
Neutrophils were the main cell population suffering from the in vitro incubation whereas mononuclear cells that include the pluripotent stem cells were relatively immune to the in vitro toxic effects of dimethyl-sulfoxide.
By reducing the volumes of both dimethyl-sulfoxide and cell lysis products, washing can also decrease the adverse reactions related to the infusion of cryopreserved units.
However, volume reducing grafts after thawing can reduce the amount of hematopoietic stem cells infused into the patients due to cell loss during manipulation.
Many studies have shown that infusing a high nucleated cell dose may be a good prognostic factor for both engraftment and survival in duct blood transplantation. it's known that the amount of cells infused during transplantation is one log but during a standard allogeneic bone marrow transplant.
Also, the manipulation may cause qualitative changes within the product which will affect engraftment. The slow engraftment due to the limited number of hematopoietic stem cells available during a single unit of duct blood may contribute to high peritransplant mortality and limit the success of duct blood transplants, especially in adults patients.
Therefore, any process which will end in hematopoietic stem cell loss or adversely affect hematopoietic stem cell viability, that is, manipulation, should be avoided especially in duct blood units with the low number of hematopoietic stem cells.
An earlier study observed delayed neutrophil recovery in three patients receiving unmanipulated duct blood. However, these patients received Methotrexate that impacts on hematopoietic recovery.
It was found that the hematopoietic recovery and survival of the recipients of unmanipulated duct blood were like those of volume reduced duct blood.
Comments
Post a Comment